| The physiology of glucagon-like peptide 1 JJ Holst Physiological reviews 87 (4), 1409-1439, 2007 | 3849 | 2007 |
| Type 2 diabetes mellitus RA DeFronzo, E Ferrannini, L Groop, RR Henry, WH Herman, JJ Holst, ... Nature reviews Disease primers 1 (1), 1-22, 2015 | 2468 | 2015 |
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. MA Nauck, MM Heimesaat, C Orskov, JJ Holst, R Ebert, W Creutzfeldt The Journal of clinical investigation 91 (1), 301-307, 1993 | 2010 | 1993 |
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study M Zander, S Madsbad, JL Madsen, JJ Holst The Lancet 359 (9309), 824-830, 2002 | 1788 | 2002 |
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. A Flint, A Raben, A Astrup, JJ Holst The Journal of clinical investigation 101 (3), 515-520, 1998 | 1779 | 1998 |
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients MA Nauck, N Kleine, C Ørskov, JJ Holst, B Willms, W Creutzfeldt Diabetologia 36, 741-744, 1993 | 1425 | 1993 |
| Glucagon-like peptide 1 (GLP-1) TD Müller, B Finan, SR Bloom, D D'Alessio, DJ Drucker, PR Flatt, ... Molecular metabolism 30, 72-130, 2019 | 1339 | 2019 |
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients MB Toft-Nielsen, MB Damholt, S Madsbad, LM Hilsted, TE Hughes, ... The Journal of Clinical Endocrinology & Metabolism 86 (8), 3717-3723, 2001 | 1240 | 2001 |
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst Diabetes 50 (3), 609-613, 2001 | 1212 | 2001 |
| Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations ER Pearson, I Flechtner, PR Njølstad, MT Malecki, SE Flanagan, B Larkin, ... New England Journal of Medicine 355 (5), 467-477, 2006 | 1208 | 2006 |
| Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects CF Deacon, MA Nauck, M Toft-Nielsen, L Pridal, B Willms, JJ Holst Diabetes 44 (9), 1126-1131, 1995 | 1182 | 1995 |
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans MA Nauck, U Niedereichholz, R Ettler, JJ Holst, C Ørskov, R Ritzel, ... American Journal of Physiology-Endocrinology and Metabolism 273 (5), E981-E988, 1997 | 1179 | 1997 |
| Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus M Gutniak, C Ørkov, JJ Holst, B Ahrén, S Efendić New England Journal of Medicine 326 (20), 1316-1322, 1992 | 1145 | 1992 |
| Inhibition of gastric inhibitory polypeptide signaling prevents obesity K Miyawaki, Y Yamada, N Ban, Y Ihara, K Tsukiyama, H Zhou, S Fujimoto, ... Nature medicine 8 (7), 738-742, 2002 | 1132 | 2002 |
| Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo CF Deacon, AH Johnsen, JJ Holst The Journal of Clinical Endocrinology & Metabolism 80 (3), 952-957, 1995 | 1088 | 1995 |
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans C Ørskov, L Rabenhøj, A Wettergren, H Kofod, JJ Holst Diabetes 43 (4), 535-539, 1994 | 1054 | 1994 |
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans JJ Holst, J Gromada American Journal of Physiology-Endocrinology And Metabolism 287 (2), E199-E206, 2004 | 954 | 2004 |
| Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man A Wettergren, B Schjoldager, PE Mortensen, J Myhre, J Christiansen, ... Digestive diseases and sciences 38 (4), 665-673, 1993 | 952 | 1993 |
| Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition RS Kootte, E Levin, J Salojärvi, LP Smits, AV Hartstra, SD Udayappan, ... Cell metabolism 26 (4), 611-619. e6, 2017 | 915 | 2017 |
| A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans C Verdich, A Flint, JP Gutzwiller, E Naslund, C Beglinger, PM Hellstrom, ... The Journal of Clinical Endocrinology & Metabolism 86 (9), 4382-4389, 2001 | 909 | 2001 |
